Non-interventional study on the Management of Advanced Prostate Cancer with Triptorelin Pamoate Three Month Formulation (PamorelinLA 11.25 mg) or Six Month Formulation (PamorelinLA 22.5 mg) with a Focus on Quality of Life, using the PORPUS Questionnaire (Patient-orientated prostate utility scale).

Trial Profile

Non-interventional study on the Management of Advanced Prostate Cancer with Triptorelin Pamoate Three Month Formulation (PamorelinLA 11.25 mg) or Six Month Formulation (PamorelinLA 22.5 mg) with a Focus on Quality of Life, using the PORPUS Questionnaire (Patient-orientated prostate utility scale).

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Sep 2016

At a glance

  • Drugs Triptorelin (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms IQUOPAM
  • Sponsors Ipsen Pharma GmbH
  • Most Recent Events

    • 06 Sep 2012 Status changed from recruiting to completed as reported by German Clinical Trials Register record.
    • 06 Jul 2012 Actual initiation date (1 Sep 2011) added as reported by German Clinical Trials Register record.
    • 06 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top